National Health Investors, Inc. (NHI) reported positive Q4 2023 results, with net income attributable to common stockholders at $0.74 per diluted share, compared to $0.04 in the same period last year. The results were driven by deferral repayments and growth in SHOP NOI. The company's financial profile remains strong, with leverage at 4.4 times net debt-to-adjusted EBITDA.
Net income attributable to common stockholders per diluted common share was $0.74, up from $0.04 in the prior year.
NAREIT FFO per diluted common share was $1.09, compared to $0.74 in the prior year.
Normalized FFO per diluted common share was $1.09, up from $0.85 in the prior year.
SHOP NOI grew 24.4% sequentially compared to Q3 2023.
NHI issued its 2024 annual guidance range, expecting NAREIT FFO per diluted common share and Normalized FFO per diluted common share in a range of $4.31 - $4.37, and Normalized FAD in a range of $191.3 million - $194.1 million.
Visualization of income flow from segment revenue to net income